BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steckelings UM, Sumners C. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin Sci (Lond) 2020;134:2987-3006. [PMID: 33210709 DOI: 10.1042/CS20200922] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Steckelings UM, Widdop RE, Sturrock ED, Lubbe L, Hussain T, Kaschina E, Unger T, Hallberg A, Carey RM, Sumners C. The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target. Pharmacol Rev 2022;74:1051-135. [PMID: 36180112 DOI: 10.1124/pharmrev.120.000281] [Reference Citation Analysis]
2 Simko F, Baka T, Stanko P, Repova K, Krajcirovicova K, Aziriova S, Domenig O, Zorad S, Adamcova M, Paulis L. Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System. Biomedicines 2022;10:1844. [DOI: 10.3390/biomedicines10081844] [Reference Citation Analysis]
3 Ünal Çetin E, Beyazit Y, Beyazit F, Tanoğlu A, Haznedaroğlu İC. The pathobiological harmony between the local pulmonary/ bone marrow RAS and its management via tissue-RAS modulating agents in COVID-19. J Health Sci Med / JHSM 2022;5:932-7. [DOI: 10.32322/jhsm.1090521] [Reference Citation Analysis]
4 Yoshihara F, Ohtsu H, Nakai M, Tsuzuki S, Hayakawa K, Terada M, Matsunaga N, Yasuda S, Ogawa H, Ohmagari N. Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 REGISTRY JAPAN. Journal of Cardiology 2022. [DOI: 10.1016/j.jjcc.2022.04.001] [Reference Citation Analysis]
5 Ulugerger Avci G, Bektan Kanat B, Suzan V, Can G, Korkmazer B, Karaali R, Tabak F, Borekci S, Aygun G, Yavuzer H, Doventas A. Clinical outcomes of geriatric patients with COVID-19: review of one-year data. Aging Clin Exp Res 2022;34:465-74. [PMID: 35064542 DOI: 10.1007/s40520-021-02047-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Simko F, Baka T. Commentary: Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells. Front Pharmacol 2022;13:842512. [DOI: 10.3389/fphar.2022.842512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Repova K, Aziriova S, Krajcirovicova K, Simko F. Cardiovascular therapeutics: A new potential for anxiety treatment? Med Res Rev 2022. [PMID: 34993995 DOI: 10.1002/med.21875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Speth RC. Renin-Angiotensin-Aldosterone System. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00160-2] [Reference Citation Analysis]
9 Tornling G, Batta R, Porter JC, Williams B, Bengtsson T, Parmar K, Kashiva R, Hallberg A, Cohrt AK, Westergaard K, Dalsgaard CJ, Raud J. Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial. EClinicalMedicine 2021;41:101152. [PMID: 34723163 DOI: 10.1016/j.eclinm.2021.101152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
10 Qu L, Chen C, Yin T, Fang Q, Hong Z, Zhou R, Tang H, Dong H. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. Int J Mol Sci 2021;22:11483. [PMID: 34768911 DOI: 10.3390/ijms222111483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Cooper SL, Boyle E, Jefferson SR, Heslop CRA, Mohan P, Mohanraj GGJ, Sidow HA, Tan RCP, Hill SJ, Woolard J. Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. Int J Mol Sci 2021;22:8255. [PMID: 34361021 DOI: 10.3390/ijms22158255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
12 Gómez-Zorita S, Milton-Laskibar I, García-Arellano L, González M, Portillo MP. An Overview of Adipose Tissue ACE2 Modulation by Diet and Obesity. Potential Implications in COVID-19 Infection and Severity. Int J Mol Sci 2021;22:7975. [PMID: 34360741 DOI: 10.3390/ijms22157975] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
13 Schober ME, Pavia AT, Bohnsack JF. Neurologic Manifestations of COVID-19 in Children: Emerging Pathophysiologic Insights. Pediatr Crit Care Med 2021;22:655-61. [PMID: 33965992 DOI: 10.1097/PCC.0000000000002774] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
14 Miedema J, Schreurs M, van der Sar-van der Brugge S, Paats M, Baart S, Bakker M, Hoek R, Dik WA, Endeman H, Van Der Velden V, van Gammeren A, Ermens A, Aerts JG, Thüsen JV. Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course. Front Immunol 2021;12:684142. [PMID: 34054876 DOI: 10.3389/fimmu.2021.684142] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
15 Simko F, Baka T. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? Clin Sci (Lond) 2021;135:1009-14. [PMID: 33881142 DOI: 10.1042/CS20210182] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
16 Davis PA, Bertoldi G, Calò LA. On the imbalanced protective arm of RAS in COVID-19: Lesson from rare genetic tubulopathies. Int J Clin Pract 2021;75:e14075. [PMID: 33887873 DOI: 10.1111/ijcp.14075] [Reference Citation Analysis]
17 Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, Hönicke AS, Müller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021;4:100100. [PMID: 33880442 DOI: 10.1016/j.jtauto.2021.100100] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 64.0] [Reference Citation Analysis]
18 Fatima N, Patel SN, Hussain T. Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling. Hypertension 2021;77:1845-56. [PMID: 33840201 DOI: 10.1161/HYPERTENSIONAHA.120.11941] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
19 Simko F, Hrenak J, Adamcova M, Paulis L. Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions. Int J Mol Sci 2021;22:3217. [PMID: 33809971 DOI: 10.3390/ijms22063217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
20 Pironti G, Andersson DC, Lund LH. Mechanistic and Therapeutic Implications of Extracellular Vesicles as a Potential Link Between Covid-19 and Cardiovascular Disease Manifestations. Front Cell Dev Biol 2021;9:640723. [PMID: 33644077 DOI: 10.3389/fcell.2021.640723] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]